San Diego, CA and Tokushima, Japan — [June 5, 2025] — GemPharmatech, a global leader in genetically engineered mouse models and preclinical research services, is proud to announce the establishment of a distributor agreement with Setsuro Tech Inc., a leading gene editing service provider based in Tokushima. This agreement marks a significant step by GemPharmatech towards serving the needs of Japan’s biomedical research community more closely and effectively.

Beginning May 1, 2025, Setsuro Tech will act as GemPharmatech’s authorized distributor for its KOAP (Knockout All Project) product line in Japan, including knockout (KO), conditional knockout (cKO), humanized, disease, and immunodeficient mouse models. Through this partnership, both companies aim to enhance accessibility to advanced research models and provide dedicated local support tailored to the preferences of Japanese institutions.

“We are honored to work alongside Setsuro Tech, whose deep understanding of the Japanese scientific landscape and commitment to technical excellence align closely with our mission to support innovative biomedical research,” said Dr. Brandy Wilkinson, CEO of GemPharmatech. “We believe this partnership will help us serve our Japanese customers with the highest standards of responsiveness, reliability, and scientific rigor.”

This collaboration is poised to significantly benefit researchers and institutions across Japan by offering more accessible and streamlined procurement of advanced genetically engineered models. It also enhances Setsuro Tech’s offerings by expanding their model portfolio, allowing them to better meet the needs of academic and industry clients.

This agreement reflects GemPharmatech’s broader vision to foster international collaboration and contribute to the advancement of life sciences through trusted local partnerships.

For further information, please visit:

• GemPharmatech: https://www.gempharmatech.com

• Setsuro Tech: https://www.setsurotech.com